Detalles de la búsqueda
1.
A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma.
Invest New Drugs
; 38(5): 1421-1429, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31984451
2.
Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial.
Lancet
; 389(10081): 1809-1820, 2017 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28385352
3.
A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia.
J Clin Endocrinol Metab
; 105(8)2020 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32589738
4.
Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action.
Menopause
; 25(8): 862-869, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29533369
5.
Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
Diabetes Care
; 29(5): 1016-23, 2006 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-16644631
6.
Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.
Diabetes
; 51(2): 443-8, 2002 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-11812753
7.
Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles.
Diabetes Care
; 25(9): 1597-602, 2002 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-12196433
8.
Insulin and insulin-like growth factor-1 action on human skeletal muscle: preferential effects of insulin-like growth factor-1 in type 2 diabetic subjects.
Metabolism
; 51(9): 1171-9, 2002 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-12200763
9.
Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.
Clin Ther
; 24(9): 1426-38, 2002 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-12380634
10.
Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study.
Endocrine
; 42(2): 366-74, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22527887
11.
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.
Endocr Relat Cancer
; 19(5): 657-66, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22807497
12.
The metabolic effects of troglitazone in patients with diabetes and end-stage renal disease.
Endocrine
; 28(2): 181-6, 2005 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-16388091
Resultados
1 -
12
de 12
1
Próxima >
>>